Over the past 2 years, commercially insured patients enrolled in plans that had value-based contracts for certain high-cost drugs had lower copays for their medications than did patients enrolled in plans without such contracts. That finding comes from “Delivering Results for Patients: The Value of Value-Based Contracts,” a new report from the Pharmaceutical Research and Manufacturers of America (PhRMA).
Over the past 2 years, commercially insured patients enrolled in plans that had value-based contracts for certain high-cost drugs had lower copays for their medications than did patients enrolled in plans without such contracts. That finding comes from “Delivering Results for Patients: The Value of Value-Based Contracts,” a report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA).
PhRMA’s report identifies the following types of value-based contracts:
According to PhRMA, value-based contracting has the potential benefit of allowing for broader access to innovative medicines by reducing the payers’ risk of suboptimal outcomes and encouraging the appropriate use of medicines. These agreements may also help to reduce medicine costs, says PhRMA, if manufacturers pay higher rebates for patients who do not meet their outcome targets. Patients could realize a savings if rebates are passed on to them.
As a result of these potential benefits, many health plans are warming to the idea of value-based arrangements, especially in the form of outcomes-based contracts, according the report. PhRMA says that, according to a 2017 Avalere Health report on payer perspectives on outcomes contracting, approximately 70% of commercial plans have a favorable view of this contract type, approximately 25% have implemented at least 1 such contract, and 30% report that they are negotiating a contract or contracts.
Among plans that have at least 1 outcomes-based contract, 55% report that they have entered into a contract that focuses on endocrine disorders—including diabetes—and another 33% are considering doing so. “If new value-based contracts are able to improve use of medicines for diabetes and reduce the burden of this disease in the United States by as little as [5%], these contracts could save nearly $9 billion annually in direct medical costs by preventing 365,000 emergency department visits, 390,000 hospital outpatient visits and 1.3 million hospital inpatient days,” according to the report.
Patients, too, could see a positive financial impact from such contracts. PhRMA says that it has worked with Avalere Health to analyze formulary coverage for existing outcomes-based contracts, including those for drugs that treat diabetes, high cholesterol, and HIV. Copays for patients enrolled in silver-level exchange plans with outcomes-based contracts were an average of 28% lower for these drugs than they were for patients enrolled in market average silver-level exchange plans.
However, barriers to value-based contracts—including concerns about how such arrangements might affect price reporting, issues with potentially implicating the federal anti-kickback statue, and uncertainty about the FDA’s rules regarding manufacturers’ communications with plans—make it difficult to accurately judge the potential that these contracts could have, says PhRMA.
“Small policy changes to modernize outdated regulations have the potential to lead to tremendous benefits for patients and the health care system,” the report concludes.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.